Key facts
- MORGAN STANLEY filed SCHEDULE 13G/A for Terns Pharmaceuticals, Inc. Common Stock (TERN).
- Disclosed ownership: 5.6%.
- Date of event: 31 Mar 2026.
MORGAN STANLEY - 31 Mar 2026 SCHEDULE 13G/A Report for Terns Pharmaceuticals, Inc. Common Stock (TERN)
- Filing Manager
- MORGAN STANLEY
- Reporting Manager
- Morgan Stanley
- Symbol
- TERN
- Shares outstanding
- 114,892,214 shares
- Disclosed Ownership
- 6,433,964 shares
- Ownership
- 5.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 12 May 2026, 11:11:04 UTC
- Date of event
- 31 Mar 2026
- Previous filing
- 07 May 2025
- SEC
- View on sec.gov
Key filing fact
MORGAN STANLEY disclosed 5.6% ownership in Terns Pharmaceuticals, Inc. Common Stock (TERN) on 31 Mar 2026.
Change
- Previous schedule filing date: 07 May 2025.
- Current filing was accepted on 12 May 2026, 11:11.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (2)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | 5.6% | 6,433,964 | 0 | 6,422,021 | Claire Gordon | Authorized Signatory, Morgan Stanley | |
| Morgan Stanley Capital Services LLC | 4.9% | 5,764,462 | 0 | 5,764,462 | Claire Gordon | Authorized Signatory, Morgan Stanley Capital Services LLC |
CIK / CUSIP context first